Guido van der Groen

Guido van der Groen

Auto-generated profile, based on publicly available information

Guido van der Groen

Institute of Tropical Medicine, Antwerp, Belgium

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 1994 in AIDS
Verified
Journal Article
Closed access
JNJohn N. Nkengasong
John N. Nkengasong
WJWouter Janssens
Wouter Janssens
LHLeo Heyndrickx
Leo Heyndrickx
KFKatrien Fransen
Katrien Fransen
PNPeter M. Ndumbe
Peter M. Ndumbe
GGGuido van der Groen
Guido van der Groen
The only two HIV-1 strains (ANT70 and MVP5180) reported to date from Cameroon are members of the outlier clade (group O). In this study, we assessed the prevalence of group O viruses and other HIV-1 subtypes in Cameroon. A phylogenetic analysis of 18 HIV-1 strains isolated from seropositive individuals from Yaoundé and Douala, Cameroon. A 900 base-pair fragment of the env gene coding for V3, V4, V5, and the beginning of gp41 of 17 out of 18 HIV-1 isolates from Cameroon was amplified, cloned and sequenced using polymerase chain reaction. A phylogenetic tree was constructed. The overall env nucleotide sequence divergence among the Cameroon isolates ranged from 6.1 to 27.5%. In a phylogenetic tree, six subtypes were identified when compared with 23 reference strains of different geographic origin. Of these 17 Cameroonian strains, 11 (61%) were of subtype A of which the interpatient distances at the sequence level varied from 6.1% to 18.3% (average, 11.9%). Three (17%) strains were of subtype F, and the other three strains (6% each) belonged to subtypes B, E and H, respectively. The remaining isolate was classified as belonging to group O, on the basis of the sequence of part of the pol gene. A very broad spectrum of different tetrameric amino-acid sequences was observed at the apex of the V3 loop. Eleven strains contained the tetrameric globally predominant GPGQ sequence at the tip of the V3 motif. Two strains had the GPGR sequence typical of the American and European HIV-1 strains. The remaining tetrameric sequences included GPGS, GSGQ, GRGQ, and GLGR. These findings on a limited number of viruses suggest extensive env gene diversity of HIV-1 strains from Cameroon, and could have implications for vaccine development in Africa.

2 July 1998 in Journal of Virological Methods
Verified
Journal Article
Closed access
EBE Beirnaert
E Beirnaert
BWB Willems
B Willems
MPM Peeters
M Peeters
ABA Bouckaert
A Bouckaert
LHL Heyndrickx
L Heyndrickx
GGG van der Groen
G van der Groen

1 January 1995 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
JNJohn N. Nkengasong
John N. Nkengasong
JAJonas Ayuk
Jonas Ayuk
GGGuido Van Der Groen
Guido Van Der Groen
HCHendrik Claeys
Hendrik Claeys
PNPhillipe Nyambi
Phillipe Nyambi
HBHans De Beenhouwer
Hans De Beenhouwer
Information is lacking on the prevalence of hepatitis C virus (HCV) infection in most African countries. An algorithm based on a combination of enzyme immunoassays (EIAs) with different formats (a commercial test, an HCV antibody [Ab] III test, and an HCV core Ab EIA) was used to estimate the prevalence of HCV infection in different population groups from southern Cameroon. An overall high prevalence was observed, with a significant increasing trend for both sexes with respect to age. A high proportion (67.4%) of HCV-positive sera were viremic as demonstrated by the reverse transcription-polymerase chain reaction. We conclude that the prevalence of HCV is high in southern Cameroon and increases linearly with age.

31 October 2001 in Journal of Medical Primatology
Verified
Journal Article
Closed access
PDF file
POPascale Ondoa
Pascale Ondoa
LKLuc Kestens
Luc Kestens
DDDavid Davis
David Davis
CVChris Vereecken
Chris Vereecken
BWBetty Willems
Betty Willems
GGGuido Van Der Groen
Guido Van Der Groen

1 August 1994 in AIDS
Verified
Journal Article
Closed access
JNJohn N. Nkengasong
John N. Nkengasong
MPMartine Peeters
Martine Peeters
PNPeter Ndumbe
Peter Ndumbe
WJWouter Janssens
Wouter Janssens
BWBetty Willems
Betty Willems
GGGuido van der Groen
Guido van der Groen
To determine the neutralizing antibody patterns to HIV-1ANT70 (ANT70) and HIV-1IIIB (IIIB) in human sera obtained from HIV-1-infected individuals from different African countries and Belgium. Second, to correlate the presence of neutralizing antibodies in sera and their ability to bind to synthetic peptides derived from eight different HIV-1 V3 loop sequences. Forty sera from Belgium and 88 obtained from seven countries in Africa were tested for their ability to neutralize ANT70 (one of the most genetically divergent HIV-1 isolates documented), and IIIB. Sera found to cross-neutralize both viruses were further challenged with four HIV-1 field isolates. All sera were tested on a panel of V3 loop peptides obtained from different HIV-1 genotypes. Four patterns of sera were identified, including 33 (26%) sera not neutralizing any of the isolates, seven (5%) sera neutralizing only ANT70, 45 (35%) sera neutralizing only IIIB, and 43 (34%) sera cross-neutralizing both isolates. Sera capable of cross-neutralizing both ANT70 and IIIB consistently neutralized other field isolates tested, with a remarkable similarity in neutralizing antibody titre. A significantly higher number of sera cross-neutralizing both ANT70 and IIIB compared with sera lacking neutralizing antibodies, reacted simultaneously in enzyme-linked immunosorbent assays (ELISA) with three or more V3 loop peptides belonging to HIV-1 strains of different genotypes. However, none of the sera cross-neutralizing ANT70 and IIIB were reactive in ELISA with the ANT70 V3 loop peptide. These results suggest that despite pronounced genomic variation of the HIV-1ANT70 isolate, there are strongly conserved neutralizing epitopes situated outside the V3 loop that are shared by other HIV-1 isolates. These findings suggest that genetic variation might be surmountable in the design of a polyvalent HIV vaccine, if neutralizing antibodies are found to be correlates of protection in HIV infection.

24 May 2002 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
POPascale Ondoa
Pascale Ondoa
DDDavid Davis
David Davis
LKLuc Kestens
Luc Kestens
CVChris Vereecken
Chris Vereecken
SRSergio Garcìa Ribas
Sergio Garcìa Ribas
GGGuido van der Groen
Guido van der Groen